Thrombogenic and endothelial damage markers in patients withischemic systolic impairment

Revista Espanola de Cardiologia

Volumn 54, Issue 10, 2001, Pages 1155-1160

  Roldán Schilling, Vanessa ^a   Marín Ortuño, Francisco ^b   Pineda Rocamora, Javier ^b   Climent Payá, Vicente E ^b   Martínez Martínez, Juan G ^b   Marco Vera, Pascual ^b   De Teresa Parreño, Luis de ^a   Sogorb Garri, Francisco ^b  

^a Hospital de San Vicente   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Fibrinogen; Heart failure; Myocardial infarction; Von Willebrand factor

Indexed keywords

BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; FIBRINOGEN; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; D DIMER; PROTHROMBIN;

ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; MIDDLE AGED; ADULT; AGE; AGED; ANTICOAGULATION; BLOOD FLOW; BLOOD LEVEL; CLINICAL FEATURE; CLINICAL STUDY; CONTROLLED STUDY; DISEASE MARKER; ECHOGRAPHY; ENDOTHELIUM INJURY; GENDER; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; SINUS RHYTHM; SYSTOLE; THEORY; THROMBOEMBOLISM; THROMBOGENICITY; TREATMENT INDICATION;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; VON WILLEBRAND FACTOR;

EID: 0034746775     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(01)76473-1     Document Type: Article

References (37)

1. Ventricular dysfunction and the risk of stroke after myocardial infarction
2. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infartction: Results of the Survival and Ventricular Enlargement Trial
3. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
4. Management of heart failure. IV. Anti-coagulation for patients with heart failure due to left ventricular systolic dysfunction
5. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patiens
6. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy
7. Hemostatic abnormalities in patients with congestive heart failure: Diagnostic significance and clinical challenge
8. Consensus recommendations for the management of chronic heart failure
9. Guías de actuación clínica de la Sociedad Española de Cardiología. Recomendaciones para el uso del tratamiento antitrombótico en cardiología
10. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited
11. Estudio del sistema fibrinolítico en pacientes con miocardiopatía dilatada
12. The influence of left ventricular filling pressure on atrial contribution to cardiac output
13. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: Implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography
14. Does atrial fibrillation confer a hypercoagulable state?
15. Hypofibrinolysis in atrial fibrillation
16. Atrial fibrillation investigators. Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooleed data from five randomized trials
17. Atrial fibrillation is associated with an increase risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials
18. Systemic embolism in chronic left ventricular aneurysm: Incidence and the role of anticoagulation
19. Haemostatic and haemodinamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation
20. Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation
21. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
22. Fibrin D-dimer: A useful clinical marker of thrombogenesis?
23. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly study
24. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
25. Effects of warfarin on markers of hypercoagulability in patients with heart failure
26. Plasma atherogenic markers iln congestive heart failure and posttransplant (heart) patients
27. Platelet function, thrombin and fibrinolytic activity in patients with heart failure
28. Effects on warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysm
29. Left ventricular function and coagulation activity in healed myocardial infarction
30. Haemostatic risk factors for cardiovascular diseases
31. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
32. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction
33. Activador tisular del plasminógeno como factor pronóstico en pacientes con infarto de miocardio
34. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
35. For the HELAS investigators. Interim results of HELAS (Heart failure Long-term Antithrombotic Study)
36. Can anticoagulant therapy modify the rates of the thromboembolic events and death in patients with chronic heart failure and sinus rhythm
37. Incidence of thromboembolic events in congestive heart failure